Year-end report October – December 2020
Curasight A/S (“Curasight” or “the Company”) hereby publishes the year-end report for the period October 1 – December 31, 2020. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “The initiation of a pre-clinical therapy study in Glioblastoma (brain cancer) during the fourth quarter marks the beginning of developing Curasight’s therapy method into a clinically useful method. Glioblastoma is challenging to treat, and there has essentially been no significant